Merck: Investigator Studies Program in Neuroscience (Insomnia)
Deadline: October 7, 2021
Category: Neuroscience; Insomnia,
The Merck Investigator Studies Program supports hypothesis-generating clinical and pre-clinical research that is initiated, designed and implemented by external investigators. Early-stage investigators and new investigators are encouraged to apply.
The following areas are of interest to the Investigator Studies Program Committee:
- Human studies that differentiate the orexin receptor (OX1R and OX2R) antagonism mechanism of action from other hypnotics, e.g., through the use of novel sleep/wake metrics or other clinical or functional outcomes.
- Studies investigating the optimal diagnosis and treatment of insomnia, treatment patterns, care pathways and biomarker changes associated with the use of an orexin receptor antagonist in subpopulations and clinical settings.
- Studies investigating real-world function and costs in subpopulations, including diseases or situations with a high prevalence of insomnia, and a high impact of insomnia treatment on health outcomes.
- Studies relevant to suvorexant that characterize insomnia by novel digital technologies including mobile devices, wearables, and remote sensing devices.
- Studies assessing the treatment of insomnia, preferably with suvorexant, using digital therapeutics or novel digital technologies to assess day-time function, activities, treatment outcomes, and clinical trial endpoints.
- Nonclinical studies investigating sleep mechanisms related to orexins and insomnia, with a focus on translational functional measures.
Please contact Daniel Hadley if you are interested in applying to this opportunity.